Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in b) Developmental delay compared with placebo or control (moderate certainty).
Methylxanthine may leads to lower any apneic episodes compared with placebo or control (low certainty).
Methylxanthine showed no clear difference in positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in death at hospital discharge compared with placebo or control (low certainty).
Methylxanthine showed no clear difference in death at hospital discharge compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
It is very uncertain whether methylxanthine changes any apneic episodes compared with placebo or control (very low certainty).
Methylxanthine may leads to lower failed apnea reduction compared with placebo or control (low certainty).
Methylxanthine may leads to lower positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).